Act on the Residence, Economic Activity and Integration of Foreigners in the Federal Territory
Residence Act. Translation provided by the Language Service of the Federal Ministry of the Interior.
Version information: The translation includes the amendment(s) to the Act by Article 3 of the Act of 6....9.2013 (Federal Law Gazette I p. 3556).
Translations may not be updated at the same time as the German legal provisions displayed on this website. To compare with the current status of the German version, see http://www.gesetze-im-internet.de/aufenthg_2004/BJNR195010004.html.
more
Global AIDS Update 2018
Closing Gaps
Breaking Barriers
Righting injustices
Date issued: 14 April 2020
The Global Fund is committed to ensuring that input from those closest to and living with HIV, tuberculosis and malaria are included in every funding request to the Global Fund. Their input is critical to ensuring that programs are effective and designed to help those m...ost impacted.
Inclusive country dialogue and the engagement of civil society, communities, and key and vulnerable populations in the development of funding requests remains a requirement for receiving financing from the Global Fund.
more
Der Artikel "Händedesinfektion unter den Bedingungen der SARS-CoV-2-Pandemie" war am 4.5.2020 online vorab erschienen und ist nun in der regulären Ausgabe des Epidemiologischen Bulletins 19/2020 zu finden.
Mund-Nasen-Bedeckung im öffentlichen Raum als weitere Komponente zur Reduktion der Übertragungen von COVID-19. Strategieergänzungen zu empfohlenen Schutzmaßnahmen und Zielen (3. Update) Das RKI empfiehlt ein generelles Tragen einer Mund-Nasen-Bedeckung (MNB) in bestimmten Situationen im öffentl...ichen Raum als einen weiteren Baustein, um Risikogruppen zu schützen und den Infektionsdruck und damit die Ausbreitungsgeschwindigkeit von COVID-19 in der Bevölkerung zu reduzieren. Diese Empfehlung beruht auf einer Neubewertung aufgrund der zunehmenden Evidenz, dass ein hoher Anteil von Übertragungen unbemerkt erfolgt, und zwar bereits vor dem Auftreten von Krankheitssymptomen. Ziel des im Epidemiologischen Bulletin 19/2020 veröffentlichten Artikels ist es, eine kurze Übersicht zum fachlichen Hintergrund der Empfehlung zu geben und zu erläutern, welche Dinge hierbei zu berücksichtigen sind.
more
Nota INformatIva Nº 13/2020 - SE/GaB/SE/mS
September 2020
El documento "Lista de productos sanitarios prioritarios para la respuesta a COVID-19 y especificaciones técnicas asociadas" complementa esta directriz.
Este documento proporciona una orientación provisional sobre la calidad, las características de rendimiento y las normas conexas de los equi...pos de protección personal (EPP) que se utilizarán en el contexto de COVID-19. Esto incluye los productos sanitarios prioritarios de la OMS, concretamente: mascarillas quirúrgicas, mascarillas no quirúrgicas, guantes, gafas, protectores faciales, batas y mascarillas N95. Está dirigido a los organismos de adquisición, los departamentos de salud laboral, los departamentos o puntos focales de prevención y control de infecciones, los administradores de los centros de salud, la ingeniería biomédica y de materiales, los fabricantes de EPI y las autoridades de salud pública, tanto a nivel nacional como de los centros.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
La presente publicación describe las medidas de bioseguridad para disminuir el riesgo de infección por COVID-19 durante la atención estomatológica., así como las actividades y procedimientos del personal que brinda atención estomatológica para disminuir el riesgo de infección por COVID-19.
La publicación describe los procedimientos estandarizados para la atención integral de las personas diagnosticadas con tuberculosis y Virus de Inmunodeficiencia Humana en los servicios de salud a nivel nacional, así como los procesos de atención integral en las personas diagnosticadas con tuberc...ulosis y virus de Inmunodeficiencia Humana (VIH), que incluyen acciones de prevención, diagnóstico, tratamiento y seguimiento.
more
Apresentação do PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 e orientações acerca dos dois
Ziel der Psychiatrieberichterstattung ist eine umfassende und transparente Darstellung der Situation sowie das Aufzeigen von Veränderungsbedarfen der psychiatrischen, psychotherapeutischen, psychosomatischen und psychosozialen Versorgung in Bayern. Ab Seite 59 wird auf die Situation von Menschen mi...t Einwanderungsgeschichte eingegangen. Herausgeber ist das Bayerische Staatsministerium für Gesundheit und Pflege.
more
El agente etiológico de la tuberculosis es el Mycobacterium tuberculosis o bacilo de Koch. Se trata de un bacilo aerobio estricto, ácido-alcohol resistente, sin movilidad, de crecimiento lento y que se inactiva con rayos ultravioleta y temperaturas mayores de 60°C.
Cases of monkeypox (MPX) acquired in the EU have recently been reported in nine EU Member States (Austria, Belgium, France, Germany, Italy, Portugal, Spain, Sweden, and the Netherlands).
Monkeypox (MPX) does not spread easily between people. Human-to-human transmission occurs through close contact ...with infectious material from skin lesions of an infected person, through respiratory droplets in prolonged face-to-face contact, and through fomites. The predominance, in the current outbreak, of diagnosed human MPX cases among men having sex with men (MSM), and the nature of the presenting lesions in some cases, suggest transmission occurred during sexual intercourse
more
Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio...n modes are transplacental or via one of more than 140 hematophagous triatomine bugs (Reduviidae: Triatominae). Triatomines acquire the parasite from mammal reservoirs due to their obligate blood-feeding (albeit triatomines can also feed on non-reservoir vertebrates such as birds and reptiles). The disease burden for CD in the Latin America and Caribbean region, based on disability-adjusted life-years (DALYs), is at least five times greater than that of malaria, and is approximately one-fifth that of HIV/AIDS. In recent decades, CD has extended to other continents outside natural reservoir or vector distributions due to human migration, with a minimum estimated 10 million individuals infected worldwide.
more
Human schistosomiasis, a parasitic and often chronic illness, is one of the major neglected tropical diseases worldwide. It is estimated that 240 million people suffer from schistosomiasis, with more than 200000 fatalities recorded each year. Schistosomiasis is caused by an infection of the blood fl...uke Schistosoma and is transmitted to humans through direct contact with infected water.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more